%0 Journal Article
%T Oncology Drugs Approved by the FDA in Early 2018
%J Archive of "American Health & Drug Benefits".
%D 2018
%X On January 12, 2018, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca) for the treatment of women with deleterious or suspected deleterious germline BRCA-positive, HER2-negative, metastatic breast cancer after receiving chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is the first FDA-approved treatment for this patient population. Like other PARP inhibitors, olaparib was previously approved for the treatment of ovarian cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207308/